Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01829295 · ClinicalTrials.gov registry record · Phase 3

Methotrexate and Mycophenolate Mofetil for UVEITIS

A Phase 3 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 3
Development phase
216
Enrollment target

NCT01829295: Completed Phase 3 study, sponsored by University of California, San Francisco.

NCT01829295 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 216 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01829295, a Phase 3 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 3
Development phase
216 participants
Enrollment target

Study Summary

In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative effectiveness trial.

Primary Outcome

Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate.

Interventions

  • DRUG Prednisone
  • DRUG Methotrexate
  • DRUG Mycophenolate mofetil

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2013-08
Est. Completion 2018-08-09
Phase Phase 3

What the finished NCT01829295 record still lists

NCT01829295 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.

NCT01829295 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01829295 about?

NCT01829295 is a clinical study titled "Methotrexate and Mycophenolate Mofetil for UVEITIS". In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uvei...

What is the current status of trial NCT01829295?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2013-08. Estimated completion is 2018-08-09.

What interventions are being tested in trial NCT01829295?

The interventions under investigation include: Prednisone (DRUG), Methotrexate (DRUG), Mycophenolate mofetil (DRUG).

Who is sponsoring clinical trial NCT01829295?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01829295's enrollment target sits among peer trials

216 1332nd of 2000 higher than 667 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02609685 · 216 participants · NA

    Active Surveillance of Papillary Thyroid Microcarcinoma

  • NCT04994873 · 216 participants · NA

    Skills to Enhance Positivity in Suicidal Youth

  • NCT05264779 · 216 participants · NA

    The Periviable GOALS Decision Support Tool

  • NCT05434130 · 216 participants · Phase 2

    Modulating Exercise Dosage to Improve Concussion Recovery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01829295, the US trial registry maintained by the National Library of Medicine. NCT01829295 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.